Company / EPS (Diluted)
Ginkgo Bioworks Holdings, Inc. EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$18.37
FY2025
5-year range
-$50.20 / -$0.10
FY2021-FY2025
Trend
+63.4%
vs FY2024
Sector context
#202 of 204
Health Care
What the data says
Among 204 Health Care companies, Ginkgo Bioworks Holdings, Inc. is in the bottom 1% for eps (diluted). EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-18.37.
Based on SEC 10-K filings.
-18.37 in FY2025.
Declined from $-1.39 to $-18.37 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 204This company -$18.37 Sector average -$1.03
▼
-1680.2% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 63.4% year-over-year.
- Ranks #202 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$18.37 | +63.4% |
| FY2024 | -$50.20 | -3511.5% |
| FY2023 | -$1.39 | -1290.0% |
| FY2022 | -$0.10 | +0.0% |
| FY2021 | -$0.10 | +0.0% |
| FY2020 | -$0.10 | +0.0% |
| FY2019 | -$0.10 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026